FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT (OF CHANG	ES IN BENEFI	CIAL OWNERSHIP

L OND ALL	NOVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response	0.5								

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

EY T (Middle)					LS INC [I	(Cricci	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Middle)						,	X	Director	10% (Owner	
.) (Middle)	2 Da	to of Farlingt Transco	ation (A)	La matho /I	2011/1001		_ x	Officer (give title below)	Other below	(specify	
, , ,		te of Earliest Transa 1/2014	iction (iv	IOHUH/I	Jay/ Year)		Chairman and CEO				
C/O ISIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT							6. Individual or Joint/Group Filing (Check Applicable				
				l Filed	(Month/Dav/Ye	6. Indiv					
(Street)					(Line)	Line)				
92010						X	, ' ' '				
								Person			
e) (Zip)											
Table I - No	n-Derivative	Securities Acc	quired	, Dis	posed of, o	or Ben	eficially (Owned			
1. Title of Security (Instr. 3)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				v	Amount (A) or (D) Pr		Price	Reported Transaction(s) (Instr. 3 and 4)			
	07/01/2014	07/01/2014	M ⁽¹⁾		15,500 ⁽¹⁾	A	\$14.47	22,441	D		
	07/01/2014	07/01/2014	S ⁽¹⁾		15,500 ⁽²⁾	D	\$35.578	.578 6,941 D			
	07/01/2014 07/01/2014 M ⁽³⁾ 200 ⁽³⁾ A \$14.47 827						I	By Wife			
	07/01/2014	07/01/2014	S ⁽³⁾		200(3)	D	\$35.55	627	I	By Wife	
Common Stock 07/01/					1,800(3)	A	\$11.27	2,427	I	By Wife	
Common Stock 07/01					1,800(3)	D	\$35.55	627	I	By Wife	
								725,391	I	By Trust	
	z) (Zip) Table I - No	92010 Table I - Non-Derivative 2. Transaction Date (Month/Day/Year) 07/01/2014 07/01/2014 07/01/2014	92010 Table I - Non-Derivative Securities Acc 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 07/01/2014 07/01/2014 07/01/2014 07/01/2014 07/01/2014 07/01/2014 07/01/2014 07/01/2014 07/01/2014 07/01/2014	92010 Table I - Non-Derivative Securities Acquired 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Execution Date, if any (Month/Day/Year) Code (8) 07/01/2014 07/01/2014 M(1) 07/01/2014 07/01/2014 S(1) 07/01/2014 07/01/2014 M(3) 07/01/2014 07/01/2014 S(3) 07/01/2014 07/01/2014 M(3)	92010 Table I - Non-Derivative Securities Acquired, Dis 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 7 Code V 07/01/2014 07/01/2014 M(1) 07/01/2014 S(1) 07/01/2014 07/01/2014 M(3) 07/01/2014 07/01/2014 S(3) 07/01/2014 07/01/2014 S(3) 07/01/2014 07/01/2014 M(3) 07/01/2014 07/01/2014 M(3) 07/01/2014 07/01/2014 M(3)	92010 Table I - Non-Derivative Securities Acquired, Disposed of, or 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date if any (Month/Day/Year) 2A. Securities A Disposed Of (Month/Day/Year) 2A. Deemed Execution Date if any (Month/Day/	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneral State (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 2. Transaction Date (Instr. 8) 2. Transaction (Code (Instr. 8) 3. Transaction (Code (Instr. 8) 4. Securities Acquired (Instr. 8) 2. Transaction (Code (Instr. 8) 3. Transaction (Code (Instr. 8) 4. Securities Acquired (Instr. 8) 2. Transaction (Code (Instr. 8) 3. Transaction (Code (Instr. 8) 4. Securities Acquired (Instr. 8) 5. Transaction (Code (Instr. 8) 6. Transaction (Code (Instr. 8) 6. Transaction (Code (Instr. 8) 7. Transaction (Code (Instr. 8) 8. Transaction (Code (Instr. 8) 9. Transacti	Solution Solution Securities Securit	Securities Sec	Securities Sec	

(e.g., puts, calls, warrants, options, convertible securities)

	(2.3.) Pares, came, came, constant community														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (right to buy)	\$14.47	07/01/2014	07/01/2014	М		15,500		01/02/2013 ⁽⁴⁾	01/02/2016	Common Stock	15,500	\$0	66,500	D	
Employee Stock Option (right to buy)	\$14.47	07/01/2014	07/01/2014	М			200	01/02/2013	01/02/2016	Common Stock	200	\$0	0	I	By Wife
Employee Stock Option (right to buy)	\$11.27	07/01/2014	07/01/2014	М			1,800	01/04/2014 ⁽⁵⁾	01/03/2017	Common Stock	1,800	\$0	4,800	I	By Wife

Explanation of Responses:

- 1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.51 to \$35.65, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- 3. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 8/6/13.
- 4. Grant of 1/2/2009 to reporting person of stock options under the Isis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2010. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 37,500 shares per year. Following this transaction, the option was exercisable as to 66,500 on 7/1/14.
- 5. Grant of 1/4/10 to reporting person's wife of stock options under the Isis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/4/11. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 1,650 shares per year. Following this transaction, the option was exercisable as to 4,800 on 7/1/2014.

Remarks:

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.